Background Ovarian cancer risk in BRCA1 and BRCA2 mutation carriers has been shown to
decrease with longer duration of oral contraceptive use. Although the effects of using oral …

Abstract Background BRCA1 and BRCA2 (BRCA) mutation carriers face a high lifetime risk
of developing ovarian cancer. Oral contraceptives are protective in this population; however …

Background Women with mutations in either the BRCA1 or the BRCA2 gene have a high
lifetime risk of ovarian cancer. Oral contraceptives protect against ovarian cancer in general …

BACKGROUND: Women with BRCA1 or BRCA2 mutations are at increased risk of breast
and ovarian cancer. Oral contraceptives (OC) use has been associated with a reduction in …

Purpose To estimate the risks of ovarian cancer and breast cancer associated with oral
contraceptive (OC) use among women at elevated risk owing to mutations in BRCA1/2 or a …

Background: Several reproductive and hormonal factors are known to be associated with
ovarian cancer risk in the general population, including parity and oral contraceptive (OC) …

Background Multiparity and the use of oral contraceptives reduce the risk of ovarian cancer,
but their effects on this risk in women with a BRCA1 or BRCA2 mutation are unclear …

It remains inconclusive whether the use of oral contraceptives (OCs) alters the risks of breast
or ovarian cancer in women with a breast cancer susceptibility gene 1 (BRCA1) or breast …

Purpose BRCA mutation carriers have an increased risk of developing breast or ovarian
cancer. Oral contraception (OC) is known to increase breast cancer and reduce ovarian …

The role of the lifetime number of ovulatory cycles has not been evaluated in the context of
BRCA‐associated ovarian cancer. Thus, we conducted a matched case–control study to …